SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJames Halstead Regulatory News (JHD)

Share Price Information for James Halstead (JHD)

Share Price is delayed by 15 minutes
Get Live Data
128.80    4.60 (3.70%)
Bid:
128.20
Ask:
129.60
Spread: 1.40 (1.092%)
Market Cap: £536.34m
JHD Live PriceLast checked at - London Stock Exchange

Intraday James Halstead Share Chart

Pre-Close Trading Statement

30 Jul 2020 07:00

RNS Number : 5073U
James Halstead PLC
30 July 2020
 

 

 

 

30 July 2020

 

Pre-Close Trading Statement and Update on Interim Dividend

 

 

James Halstead plc, the commercial flooring manufacturer and distributor, is providing the following trading update ahead of its final results for the year ended 30 June 2020.

 

Since the Interim Report issued on 31 March much has happened. As we went into the early stages of the pandemic we were conscious of how cash flow would be affected and accordingly took decisive action on spending. Capital expenditure was curtailed, and all discretionary expenses such as marketing were cut. Spending on safety measures increased to ensure our sites were more Covid-19 resistant. Initially a primary concern was cash inflow and it is pleasing to report that customers did not, in general, hold up payments and that the various initiatives by governments in the territories in which we operate provided liquidity. At 30 June 2020 cash balances are slightly ahead of the levels at 31 December 2019. The countries in which our businesses were completely closed were few, with New Zealand being the most significant. There were several UK and international government cash flow initiatives in which we participated - the most significant being the VAT deferral in the UK (March - June) and in Germany (April - June). The German deferral was paid in June and at the end of June the UK deferral amounts to around £1.9 million.

 

Looking now at how our businesses have been affected in more detail:

 

The UK, which represents around 30-35% of turnover, faced significant disruption: almost all of our customers are distributors and through April and into May many were closed. Turnover, in the UK, in those months dropped by up to 65% (versus the comparable period last year) but we continued production to focus on the type of product that was anticipated to remain in demand. In June the UK turnover had recovered to approximately 80% of the prior year.

 

Our direct exports (i.e. to non- Group companies) continued with only a 5 - 10% reduction versus last year in the April- May period. In terms of our overseas based businesses most continued to trade, albeit it with reduced manning levels. In the core lock-down period (i.e. April- May) sales were broadly 20% below the prior year comparative with the full lock-down of New Zealand having an effect. In June our overseas businesses recovered to 90% of the prior year.

 

The preparations made by many governments for the onset of the pandemic did lead to an uplift in the sales of our product to the health and medical research sectors. Normally this sector would represent around 30% of our sheet vinyl sales but from April to June it was much more significant. As well as the supply of sheet vinyl to the NHS across the UK and significant supplies to Ireland, we have supplied new hospital facilities across the globe including Brazil, Argentina, Chile, Mexico, Italy, South Africa, Qatar and the UAE. This was not sufficient to offset the shortfall in business of other sectors which were closed.

 

In terms of overall turnover during the period April to June we averaged just over 70% of the prior year. In terms of the bottom line in this period, profit before tax was just under 50% of the prior year comparative. Cash levels have been preserved.

 

July has seen the position in terms of trading continue to improve as the distribution base in the UK started to fully re-open and in recent weeks we have seen UK sales average over 90% of the comparative. Looking at our main businesses overseas (Germany, Australia and New Zealand) the level is near parity with the comparatives.

 

It is still too early to be confident that the worst is over but it is clear that, to date, this situation is far better than we envisaged four months ago. This has been one of the most testing periods in our long history and many of our staff have put in the most commendable of efforts mobilising direct shipments not just across the UK but to far parts of the world. Whether it was the drivers and warehouse staff coming in late on a bank holiday weekend to ship Polyflor to the NHS or the health and safety teams keeping our people safe - our thanks.

 

Finally, in our Interim Statement our Chairman noted that we would declare a first interim dividend of 2.125p per share representing half the dividend we would otherwise have declared and to review a second equivalent payment of a second interim. These dividends reflected a first half year of record sales and profit. Given the improvement in trading conditions and the cash levels we, as a Board, are sufficiently confident now to declare a second interim dividend of 2.125p which will be payable on 10 September 2020 to shareholders on the register at 21 August 2020.

 

  

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. 

 

 

Enquiries:

 

 

James Halstead plc

Telephone: 0161 767 2500

Mark Halstead, Chief Executive

 

Gordon Oliver, Finance Director

 

 

 

Hudson Sandler

Telephone: 020 7796 4133

Nick Lyon

 

Nick Moore

 

 

 

Panmure Gordon (Nominated advisor and broker)

Telephone: 020 7886 2500

 

 

Dominic Morley

 

 

 

WH Ireland (Broker)

 

Ben Thorne

Chris Hardie

Telephone: 020 7614 5900

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLKLFLBDLZBBF
Date   Source Headline
25th Jan 20107:00 amRNSPre-close Trading Statement
4th Jan 20107:00 amRNSBlocklisting Interim Review
31st Dec 20097:00 amRNSTotal Voting Rights
18th Dec 20094:00 pmRNSAnnual Report and Accounts
14th Dec 200911:30 amRNSDirector's shareholding
10th Dec 20093:00 pmRNSDirector's shareholding
7th Dec 20091:50 pmRNSDirector's shareholding
4th Dec 20091:00 pmRNSDividend Declaration
4th Dec 20097:00 amRNSAGM Statement
12th Oct 200912:00 pmRNSDirector/PDMR Shareholding
29th Sep 20097:00 amRNSPreliminary Results
17th Sep 200911:37 amRNSNotice of Preliminary Results
29th Jul 20097:00 amRNSPre-Close Trading Update
1st Jul 200912:30 pmRNSBlocklisting Interim Review
30th Mar 20094:45 pmRNSDividend Declaration - Correction
30th Mar 20097:00 amRNSInterim Results
17th Mar 20093:12 pmRNSNotice of Results
26th Feb 20098:00 amRNSBlocklisting Interim Review
28th Jan 20097:00 amRNSPre-close Trading Statement
22nd Dec 200812:30 pmRNSAnnual Report and Accounts
10th Dec 20087:00 amRNSAGM Statement
8th Oct 200812:00 pmRNSDirector/PDMR Shareholding
6th Oct 20085:00 pmRNSDirector/PDMR Shareholding
30th Sep 20085:08 pmRNSDirectors' Dealings
30th Sep 20087:00 amRNSFinal Results
24th Sep 20087:00 amRNSExecutive Board Appointment
19th Sep 20084:50 pmRNSSecond Price Monitoring Extn
19th Sep 20084:35 pmRNSPrice Monitoring Extension
16th Sep 200810:00 amRNSNotice of Results
4th Sep 20087:00 amRNSNotice of Results
31st Jul 20087:00 amRNSTotal Voting Rights
3rd Jul 20081:00 pmRNSBlocklisting Interim Review
1st Jul 20087:00 amRNSTrading Statement
11th Jun 20081:00 pmRNSAdditional Listing
30th May 200810:58 amRNSTotal Voting Rights
14th May 20087:00 amRNSDirector/PDMR Shareholding
31st Mar 20087:00 amRNSInterim Results
1st Feb 20084:50 pmRNSTotal Voting Rights
31st Jan 20083:49 pmRNSAdditional Listing
30th Jan 20082:16 pmRNSDirector/PDMR Shareholding
28th Jan 20087:00 amRNSPre-close Trading Update
23rd Jan 20084:31 pmRNSBlock Listing Returns
15th Jan 20081:11 pmRNSDirector/PDMR Shareholding
7th Jan 200812:43 pmRNSDirector/PDMR Shareholding
7th Dec 20077:01 amRNSAGM Statement
15th Nov 200710:56 amRNSAnnual Report and Accounts
1st Oct 20077:01 amRNSFinal Results
10th Sep 20079:38 amRNSNotice of Results
31st Aug 20073:33 pmRNSTotal Voting Rights
23rd Aug 20071:21 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.